Sökning: (WFRF:(Onsrud M.)) >
Randomized study on...
Randomized study on adjuvant chemotherapy in stage I high-risk ovarian cancer with evaluation of DNA-ploidy as prognostic instrument
-
- Tropé, C (författare)
- Norwegian Radium Hospital
-
Kaern, J (författare)
-
- Hogberg, T (författare)
- Lund University,Lunds universitet
-
visa fler...
-
Abeler, V (författare)
-
Hagen, B (författare)
-
Kristensen, G (författare)
-
Onsrud, M (författare)
-
Pettersen, E (författare)
-
Rosenberg, P (författare)
-
Sandvei, R (författare)
-
Sundfor, K (författare)
-
Vergote, I (författare)
-
visa färre...
-
(creator_code:org_t)
- Elsevier BV, 2000
- 2000
- Engelska 8 s.
-
Ingår i: Annals of oncology : official journal of the European Society for Medical Oncology. - : Elsevier BV. - 0923-7534. ; 11:3, s. 8-281
- Relaterad länk:
-
http://dx.doi.org/10...
-
visa fler...
-
https://doi.org/10.1...
-
https://lup.lub.lu.s...
-
https://doi.org/10.1...
-
visa färre...
Abstract
Ämnesord
Stäng
- PURPOSE: Adjuvant chemotherapy versus observation and chemotherapy at progression was evaluated in 162 patients in a prospective randomized multicenter study. We also evaluated DNA-measurements as an additional prognostic factor.PATIENTS AND METHODS: Patients received adjuvant carboplatin AUC 7 every 28 days for six courses (n = 81) or no adjuvant treatment (n = 81). Eligibility included surgically staged and treated patients with FIGO stage I disease, grade 1 aneuploid or grade 2 or 3 non-clear cell carcinomas or clear cell carcinomas. Disease-free (DFS) and disease-specific (DSS) survival were end-points.RESULTS: Median follow-up time was 46 months and progression was observed in 20 patients in the treatment group and 19 in the control group. Estimated five-year DFS and DSS were 70% and 86% in the treatment group and 71% and 85% in the control group. The hazard ratio was 0.98 (95% confidence interval (95% CI): 0.52-1.83) regarding DFS and 0.94 (95% CI: 0.37-2.36) regarding DSS. No significant differences in DFS or DSS could be seen when the log-rank test was stratified for prognostic variables. Therefore, data from both groups were pooled for the analysis of prognostic factors. DNA-ploidy (P = 0.003), extracapsular growth (P = 0.005), tumor rupture (P = 0.04), and WHO histologic grade (P = 0.04) were significant independent prognostic factors for DFS with P < 0.0001 for the model in the multivariate Cox analysis. FIGO substage (P = 0.01), DNA ploidy (P < 0.05), and histologic grade (P = 0.05) were prognostic for DSS with a P-value for the model < 0.0001.CONCLUSIONS: Due to the small number of patients the study was inconclusive as regards the question of adjuvant chemotherapy. The survival curves were superimposable, but with wide confidence intervals. DNA-ploidy adds objective independent prognostic information regarding both DFS and DSS in early ovarian cancer.
Nyckelord
- Adenocarcinoma/drug therapy
- Adult
- Aged
- Analysis of Variance
- Antineoplastic Agents/therapeutic use
- Carboplatin/therapeutic use
- Chemotherapy, Adjuvant
- DNA, Neoplasm/genetics
- Female
- Humans
- Middle Aged
- Neoplasm Staging
- Ovarian Neoplasms/drug therapy
- Ploidies
- Prognosis
- Prospective Studies
- Risk Factors
- Survival Analysis
Publikations- och innehållstyp
- art (ämneskategori)
- ref (ämneskategori)
Hitta via bibliotek
Till lärosätets databas
- Av författaren/redakt...
-
Tropé, C
-
Kaern, J
-
Hogberg, T
-
Abeler, V
-
Hagen, B
-
Kristensen, G
-
visa fler...
-
Onsrud, M
-
Pettersen, E
-
Rosenberg, P
-
Sandvei, R
-
Sundfor, K
-
Vergote, I
-
visa färre...
- Artiklar i publikationen
-
Annals of oncolo ...
- Av lärosätet
-
Lunds universitet